

## Financial Calendar 2012

**Leuven, Belgium – January 05<sup>th</sup>, 2012** – ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, today announces its Financial Calendar for 2012.

ThromboGenics intends to issue the following financial releases for the 2012 period, on the dates set out below. Please note that all releases will be made after closing of the market.

<b>DATE</b>	<b>SUBJECT</b>
Thursday 08 March 2012	Full Year Results 2011
Wednesday 2 May 2012	General Shareholders Meeting 2012
Thursday 10 May 2012	Business Update H1
Thursday 30 August 2012	Half Year Results 2012
Thursday 08 November 2012	Business Update H2

- ends -

### For further information please contact:

**ThromboGenics**  
Chris Buyse, Chief Financial Officer

Tel. : +32 (0) 16 75 13 10  
Fax : +32 (0) 16 75 13 11  
chris.buyse@thrombogenics.com

**Citigate Dewe Rogerson**  
David Dible / Nina Enegren

Tel: +44 (0) 207 638 95 71  
nina.enegren@citigatedr.co.uk

### About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative ophthalmic medicines. The Company's lead product ocriplasmin has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA has been filed in the U.S. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International. These include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PIGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at [www.thrombogenics.com](http://www.thrombogenics.com).